Evidence map›Paper›PMID 31087189›Full record

ArticleFamilial cancer2019

The incidence of consecutive manifestations in Von Hippel-Lindau disease.

Anouk N A van der Horst-Schrivers, Wim J Sluiter, Roeliene C Kruizinga, Rachel S van Leeuwaarde, Rachel Giles, Maran J W Olderode-Berends, Thera P Links

Open access · hybridAbstract read
In one paragraph

Article in Familial cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Loss of endothelial glucocorticoid receptor accelerates organ fibrosis inAmerican journal of physiology. Renal physiology · 2023
    Article
  5. Article
  6. Loss of endothelial glucocorticoid receptor accelerates organ fibrosis inbioRxiv : the preprint server for biology · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Anouk N A van der Horst-SchriversDepartment of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Wim J SluiterDepartment of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Roeliene C KruizingaDepartment of Geriatric Medicine, Amsterdam UMC, Free University Amsterdam, Amsterdam, The Netherlands.
Rachel S van LeeuwaardeDepartment of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Rachel GilesDepartment of Nephrology, University Medical Center Utrecht, Utrecht, The Netherlands.
Maran J W Olderode-BerendsDepartment of Medical Genetics, University Medical Center Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Thera P LinksDepartment of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. t.p.links@umcg.nl.
University Medical Center Groningen · NLUniversity Medical Center Utrecht · NLAmsterdam University Medical Centers · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Von Hippel-Lindau (VHL) disease is an autosomal dominant rare tumor syndrome characterized by high penetrance. VHL mutation carriers develop numerous manifestations in multiple organs during life. The natural course of development of new and growth of existing VHL-related manifestations is still unclear. In this study we aimed to gain insight into the development of subsequent manifestations in VHL disease. We retrospectively scored each new VHL-related manifestation as detected by standard follow-up (retina, central nervous system, kidneys and pancreas, excluding adrenal and endolymfatic sac manifestations) in 75 VHL mutation carriers. The Kaplan-Meier method was used to plot the cumulative proportions of all consecutive manifestations in each organ against age. The cumulative average number of manifestations in all organs during life was calculated by summating these cumulative proportions. Poisson model parameters were used to calculate average time to the detection of consecutive VHL manifestations in each organ. Consecutive VHL-related kidney and retina manifestations during life occur linearly according to Poisson distribution model. The total number of VHL manifestations rises linearly, with an average of seven VHL-related lesions at age 60 years. The incidence of consecutive VHL-related manifestations is constant during life in VHL mutation carriers. Our data is consistent with the notion that somatic inactivation of the remaining allele (Knudson's "two-hit" hypothesis) is the determining factor in developing new VHL-related manifestations.

Indexed as

AdolescentAdultAgedAge FactorsCentral Nervous System NeoplasmsDisease ProgressionFemaleHemangioblastomaHeterozygoteHumansKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedPancreatic NeoplasmsRetinal NeoplasmsDisease progressionSurveillanceVHL-related manifestationsVon Hippel-Lindau disease

Identifiers

PMID31087189
PMCPMC6560011
OpenAlexW2946696945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.